Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

NCT07655622 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Vebreltinib
DRUG: Furmonertinib 80mg

Sponsor

Second Affiliated Hospital of Nanchang University

Collaborators

[object Object]